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TGFβ signaling regulates central cellular processes such as proliferation and extracellular matrix production during development of the
orofacial region. Extracellular TGFβ binds to cell surface receptors to activate the nucleocytoplasmic Smad proteins that, along with other
transcription factors and cofactors, bind specific DNA sequences in the promoters of target genes to regulate their expression. To determine the
identity of Smad binding proteins that regulate TGFβ signaling in developing murine orofacial tissue, a yeast two-hybrid screening approach was
employed. The PR-domain containing protein, PRDM16/MEL1 was identified as a novel Smad binding protein. The interaction between
PRDM16/MEL1 and Smad 3 was confirmed by GST pull-down assays. The expression of PRDM16/MEL1 was detected in developing orofacial
tissue by both Northern blot and in situ hybridization. PRDM16/MEL1 was constitutively expressed in orofacial tissue on E12.5–E14.5 as well as
other embryonic tissues such as heart, brain, liver, and limb buds. Taken together, these results demonstrate that PRDM16/MEL1 is a Smad
binding protein that may be important for development of orofacial structures through modulation of the TGFβ signaling pathway.
© 2007 Elsevier B.V. All rights reserved.Keywords: TGFβ; Smad; PRDM16; MEL1; Orofacial1. Introduction
Members of the transforming growth factor β (TGFβ) family
of secreted cytokines modulate multiple developmental pro-
cesses critical to orofacial ontogeny [1–4]. Extracellular TGFβ
ligands bind to a type II TGFβ receptor (TβRII) to promote
heterodimerization with a TGFβ type I receptor (TβRI), that
then phosphorylates Smads 2 and 3, thus exposing the Smad 4
binding surface and the nuclear import signal [5]. In the nucleus,
Smads bind to additional transcription factors/cofactors such as
FAST1 and CBP/p300, creating a complex which then binds toAbbreviations: PRDM16, PR-domain containing protein-16; MEL1, MDS1/
Evi1-like protein; TGFβ, transforming growth factor β; GST, glutathione
S-transferase; CBP, CREB binding protein; DIG, digoxigenin; kDa, kiloDalton;
kb, kilobase; E, embryonic day; GCNF, germ cell nuclear factor
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doi:10.1016/j.bbamcr.2007.03.016specific nucleotide sequences within the promoter of target
genes [6,7]. The Smad/CBP/p300 complex binds to additional
proteins such as histone acetyltransferases (HAT) and RNA
polymerase II [8,9]. Although Smad 3 has intrinsic DNA
binding ability, the affinity is low, and Smad 2 has even weaker
DNA affinity because of the presence of an amino acid insert
within the DNA binding domain [10]. Therefore, the interaction
between Smads and other transcription factors and cofactors is
essential for high affinity, specific binding of Smads to DNA.
The identification of these cofactors is required to define tissue
and cell-specific effects mediated by TGFβ.
The secondary palate originates from the maxillary processes
on days 11.5–12.5 in mice with the initial phase of growth
characterized by cell proliferation and extracellular matrix
production. Growth proceeds through E13.5 and by E14.5 the
palatal processes reorient from their position alongside the
tongue to meet and fuse above the tongue thereby separating the
oral and nasal cavities. Perturbations of this sequence of events
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palate and orofacial development from control of cell
proliferation [1], extracellular matrix production [4], and fusion
of the shelves [11]. In order to identify novel Smad binding
proteins which would better define the means by which TGFβ
regulates this multiplicity of developmental processes in
orofacial tissue, a yeast two-hybrid screen was performed
using the MH2 domain of Smad 3 as a “bait” to screen a cDNA
expression library prepared from orofacial tissue from E11.5–
E13.5 murine embryos. Several novel Smad binding proteins
have recently been reported [12–14]. Here we report the
identification of PRDM16 (also called MEL1) as a Smad
binding protein and offer a preliminary analysis of its
expression pattern in developing murine orofacial tissue and
discuss its possible function in TGFβ signaling.
2. Methods
2.1. Animals
ICR mice were obtained from Harlan Laboratories (Indianapolis, IN) and
housed at an ambient temperature of 22 °C with a 12-h light/dark cycle with
access to food and water ad libitum. For timed matings, mature male and female
mice were housed overnight and the presence of a vaginal plug the following
morning was taken as evidence of mating and designated embryonic day 0.5
(E0.5). Pregnant mice were euthanized on various days of gestation, embryos
removed, and palatal tissue microdissected and prepared for either Western
blotting or Northern blotting as described below.
2.2. Yeast two-hybrid assay
Details of the yeast two-hybrid screen, including construction of the
expression library and bait vectors have been described in detail previously [12].
In brief, pGBKT7-Smad 3 MH2 was transformed into Saccharomyces
cerevisiae (strain AH109) along with the murine orofacial expression library
in pGADT7. Transformants were plated on yeast medium in the absence of
histidine, leucine, tryptophan, and adenine and in the presence of 2.5 mM 3-
amino-1,2,4-triazole and 20 μg/ml X-α-gal according to instructions provided
by the manufacturer (Matchmaker System 3, Clontech Laboratories, Mountain
View, CA). Approximately 5×105 yeast transformants were screened, and blue
colonies maintaining the His+/Leu+/Trp+/Ade+ phenotype were sequenced and
verified for interaction with Smad 3 MH2.
2.3. Glutathione S-transferase (GST) pull-down assay
In vitro interaction between PRDM16/MEL1 and Smads was demonstrated
by a GST pull-down assay using GST-Smad fusion proteins and in vitro
translated, [35S]methionine-labeled PRDM16/MEL1. The preparation and
purification of GST-fusion protein constructs for Smads 1, 2, 3, 4, and 7 has
been described previously [13]. GST-GCNF was prepared in the same way
except that it was induced with 300 μM IPTG for 3 h at 37 °C. [35S]methionine-
labeled PRDM16/MEL1 was prepared by in vitro translation using the TNT T7
Coupled Reticulocyte Lysate System (Promega Corp., Madison, WI). One μg of
purified GST-Smad bound to glutathione–Sepharose (Amersham Biosciences,
Piscataway, NJ) was mixed with 5 μl [35S]methionine-labeled PRDM16/MEL1
for 1 h at 4 °C in binding buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 0.1% NP-
40, 1 mM dithiothreitol, 10% glycerol, 1 mM EDTA, 2.5 mM MgCl2, 1 μg/ml
aprotinin, and 1 μg/ml leupeptin). The complex was washed three times with
binding buffer and immobilized proteins were liberated by heating in 2×
Laemmli sample loading buffer [15] and separated on an 8–16% polyacrylamide
gel under reducing/denaturing conditions. Gels were fixed for 30 min with 50%
methanol:10% acetic acid and exposed to Kodak X-Omat AR film for 2 days at
−80 °C. Following autoradiography, dried gels were stained with Coomassie
blue to compare the loading efficiency for each sample.2.4. PRDM16/MEL1 riboprobe
For in situ hybridization and Northern blotting experiments, a 508-bp
EcoRI–SacII restriction fragment of murine PRDM16/MEL1 corresponding to
bases 1963–2470 was subcloned from the yeast two hybrid vector, pGADT7,
into the transcription vector, pSPT-18 (Roche Diagnostics, Indianapolis, IN).
Sense and antisense riboprobes were prepared with the DIG RNA labeling kit
according to the manufacturer's instructions (Roche Diagnostics) and purified
by multiple LiCl precipitations. Yields were determined with a NanoDrop ND-
1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE) and the
integrity of the riboprobes was assessed by agarose gel electrophoresis.
Preparations that yielded a single transcript were used for these studies.
2.5. Northern blotting
Total RNA was purified from dissected palatal tissue using the RNeasy
Protect RNA purification system (Qiagen, Inc., Valencia, CA). Ten μg was
separated on a 1.1% agarose-formaldehyde gel and transferred to a nylon
membrane (Hybond-N+, Amersham Biosciences-GE Healthcare Bio-Sciences
Corp. Piscataway, NJ) according to established procedures [16]. Following
capillary transfer and UV crosslinking, the membrane was blocked with DIG
Easy Hyb (Roche Diagnostics), hybridized to a DIG-labelled PRDM16/MEL1
antisense riboprobe (100 ng/ml, overnight, at 65 °C), washed and processed
with the DIG Wash and Block buffer set (Roche Diagnostics), and developed
with CDP-Star (Roche Diagnostics). Membranes were exposed to film or
images captured with a Kodak Image Station 440-CF and analyzed with the
Kodak 1D 3.6 software package (Kodak, Rochester, NY). To assess the equality
of RNA loading and transfer, membranes were hybridized to a DIG-labelled
338-nucleotide β-actin antisense riboprobe (Ambion, Inc., Austin, TX) which
detects a 2.1-kb transcript. Densitometric analysis was performed with NIH
Image 1.62f.
2.6. In situ hybridization
Murine embryos of the appropriate gestational age were removed and tissue
dissected (primary and secondary palates and maxilla), crosslinked overnight
with 4% paraformaldehyde-PBS, rinsed with PBT (PBS+0.1% Tween-20), and
bleached in 6% (v/v) H2O2 for 1 h. Tissue was then digested with 50 μg/ml
proteinase K for 10 min and post-fixed with 4% paraformaldehyde/0.2%
glutaraldehyde for 20 min at room temperature. Tissue was then incubated
overnight in a solution that contained 1 μg/ml DIG-labelled PRDM16/MEL1
riboprobe at 65 °C, washed thoroughly and incubated overnight again with
alkaline phosphatase-conjugated anti-digoxigenin antibody (1:2000 dilution;
Roche Diagnostics). Color development was initiated by the addition of
375 μg/ml nitro blue tetrazolium chloride, 475 μg/ml 5-Bromo-4-chloro-3-
indolyl phosphate (added from a 50× stock solution, Roche Diagnostics) and
2 mM tetramisole.
2.7. Luciferase reporter assay
For luciferase reporter assays, primary cultures of murine embryonic
maxillary mesenchyme (MEMM) were established as previously reported [17]
and plated at a density of approximately 7,000 cells/cm2 in a 6-well tissue
culture plate and incubated until they were ∼70% confluent. Each well was
transfected with DNA plasmids (1 μg p3TP-lux and 50 ng pRL-CMV) and
siRNAs (100 nM PRDM16/MEL1 or control) with the lipophilic transfection
reagent, Effectene (Qiagen Inc.). p3TP-lux is a TGFß reporter construct that
drives the Smad-dependent expression of firefly luciferase and pRL-CMV is a
control plasmid for transfection efficiency that contains the cDNA for Renilla
luciferase (Promega Corp., Madison, WI). siRNAs targeting murine PRDM16/
MEL1 and, separately, a non-targeting control siRNA were obtained from
Dharmacon, Inc. (Lafayette, CO). PRDM16/MEL1 ONTARGETplus™
siRNAs are composed of a pool of four individual siRNAs, specific to different
regions of their respective mRNA, and are designed to minimize off-target
effects. Forty-eight hours post-transfection, cells were rinsed with fresh culture
medium and treated with 2 ng/ml porcine TGFβ1 (R&D Systems Inc.,
Minneapolis, MN) for an additional 24 h. Each well was rinsed twice with PBS,
Fig. 1. Results of a yeast two hybrid assay demonstrating interaction between
Smad 3 and PRDM16/MEL1. Cultures of S. cerevisiae were co-transformed
with pGADT7-PRDM16/MEL1 and pGBKT7-Smad3 MH2, pGBKT7-Smad3
(full-length), pGBKT7-lamin C, or pGBKT7 and plated under low stringency
conditions. Colonies that proliferated were streaked and grown under high
stringency conditions and in the presence of X-α-gal (shown). Yeast growth was
observed only when pGADT7-PRDM16/MEL1 was co-transformed with
pGBKT7-Smad3 MH2 and, to a lesser extent, pGBKT7-Smad3 (full-length)
demonstrating a specific interaction between PRDM16/MEL1 and Smad 3.
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Assay System (Promega). Firefly luciferase activity is reported after normal-
ization to control, Renilla, luciferase activity for each sample. Each condition
was assayed in triplicate and the experiment was performed twice with
comparable results. To assess the efficiency of PRDM16/MEL1 mRNA
knockdown, duplicate wells were analyzed by RT-PCR. The sequences of the
individual siRNAs in the non-targeting control were (sense strand): 5′-
UGUUUACAUGUCGACUAA-3′; 5′-UGGUUUACAUGUUUUCUGA-3′;
5′-UGGUUUACAUGUUUUCCUA-3′; and 5′-UGGUUUACAUGUUGU-
GUGA (sequences provided by Dharmacon, Inc.).
2.8. RT-PCR
Total RNA was purified from siRNA-transfected MEMM cells using the
RNeasy Protect purification system (Qiagen Inc.). cDNAs were synthesized
using the SuperScript first strand cDNA synthesis system (Gibco Invitrogen
Corp., Gaithersburg, MD) and used as the template in real-time PCR assays
with probe:primer pairs purchased from Applied Biosystems (Foster City, CA)
and analyzed using the ABI Prism 7000 Sequence Detection System (Applied
Biosystems). All data were normalized to the amplification signal from
GAPDH and fold-change values were determined by the ΔΔCt method [18].Fig. 2. PRDM16/MEL1 domain structure. Murine PRDM16 (MEL1) contains at lea
domain (PRD) and two DNA binding domains (DBD1 and DBD2). In addition, it
domain (AD). The PRDM16/MEL1 cDNA clone isolated from the yeast two hybrid
valine-655 (indicated by the arrow) and continues through the carboxyl terminus (le3. Results
3.1. Identification of PRDM16/MEL1 as a Smad binding
protein
TGFβ signaling leads to disparate cellular outcomes in the
developing embryo depending on the tissue and stage of
gestation. Specificity is achieved through the interaction of
Smads with cell- and stage-specific proteins. The goal of this
study was to identify Smad binding proteins that are required for
TGFβ regulation of orofacial development. A yeast two-hybrid
screen with the MH2 domain of the TGFβ-regulated Smad 3
and an expression library constructed from E11.5 to E13.5
embryonic murine orofacial RNA was performed. Several
unique Smad binding proteins were identified and their
identities and potential role in TGFβ signaling have been
recently published [12–14,19]. In the current study, evidence is
provided to demonstrate that the PR domain containing protein
PRDM16 [PR domain containing protein-16; also known as
MEL1 [20]] is a Smad binding protein. PRDM16/MEL1 bound
to the MH2 domain and, to a lesser extent, full-length Smad 3 in
a yeast two-hybrid assay (Fig. 1). No interaction was observed
with a control protein, Lamin C. When PRDM16/MEL1 was
co-expressed with the empty bait vector, pGBKT7, no yeast
growth was observed, demonstrating that PRDM16/MEL1
alone was unable to activate transcription in this assay. The
PRDM16/MEL1 clone isolated from this screen contains
nucleotide bases 1,957–3,825 (amino acids 655–1,275) of the
coding region of the published murine PRDM16/MEL1 se-
quence (NCBI identifier NM_027504) and approximately
600 bp of 3′ untranslated sequence. [35S]-labeled PRDM16/
MEL1, in vitro translated and used for GST pull-down
contained the repressor domain, DNA binding domain-2, and
the activation domain, but was missing the PR domain and
DNA binding domain-1 as well as the proline-rich region (see
Fig. 2). The interaction between PRDM16/MEL1 and Smad 3
was confirmed with a GST pull down assay (Fig. 3). Purified,
recombinant GST-Smad fusion proteins bound to glutathione
beads were incubated with in vitro translated, [35S]-methionine
labeled PRDM16/MEL1 and isolated by centrifugation. Fig. 3A
demonstrates that PRDM16/MEL1 binds full-length Smads 2,
3, and 7 (lanes 4, 6, and 10, respectively). Minimal binding was
observed with full-length Smads 1 and 4 and a mutant Smad 3
that is missing the MH2 domain (Smad 3 ΔMH2) (lanes 2, 8,st 6 distinct amino acid domains, as indicated. It contains the characteristic PR
contains a proline-rich domain (PRR), a repressor domain (RD), and an acidic
screen with Smad 3 MH2 as the bait codes for a truncated protein that starts at
ucine-1275).
Fig. 3. GST pull-down assay demonstrating interaction between Smad 3 and PRDM16/MEL1. In vitro translated, [35S]-labeled PRDM16/MEL1 was prepared and
mixed with glutathione-Sepharose-immobilized GST-Smads. GST-Smad bound [35S]-PRDM16/MEL1 was detected by SDS-PAGE and autoradiography. Input (lane
1, panels A and B) represents the [35S]-PRDM16/MEL1 signal from 10% of the amount added to each sample. Panel A: PRDM16/MEL1 bound to full-length TGFß-
regulated Smad 2 (lane 4) and Smad 3 (lane 6), and the inhibitory Smad 7 (lane 10). Weak or no interaction was observed with full-length Smad 1 (lane 2) and Smad 4
(lane 8) and a mutant Smad 3 missing the MH2 domain (Smad 3 ΔMH2, lane 12). A higher extent of binding was found with the MH2 domains of Smad 1 (lane 3),
Smad 2 (lane 5), and Smad 3 (lane 7). Lane 13 is GSTalone and represents background binding. Panel B: additional control demonstrating only background binding to
an unrelated protein, GCNF (lane 3).
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GST-GCNF or GST alone was observed (Fig. 3B, lanes 3 and
4). A higher extent of binding was found with the MH2 domains
of Smads 1, 2, and 3 (lanes 3, 5 and 7, respectively). These data
demonstrate that PRDM16/MEL1 interacts with the MH2 do-
main of these Smads.
To determine the temporal expression pattern of PRDM16/
MEL1 mRNA, purified total RNA from microdissected
orofacial tissue from E12.5 to E14.5 murine embryos (three
independent litters from each day) was analyzed by Northern
blotting with a PRDM16/MEL1 antisense, DIG-labelled, ribop-Fig. 4. Northern blot analysis of RNA purified from isolated developing murine
embryonic orofacial tissue. To determine the temporal expression of PRDM16/
MEL1 mRNA transcripts, E12.5–E14.5 orofacial tissue (Panel A) or additional
tissues from E14.5 embryos (Panel B) was dissected and total RNA purified and
analyzed by Northern blotting with a PRDM16/MEL1 riboprobe. To assess the
loading/transfer efficiency, the RNA blots were also probed with a β-actin-
specific riboprobe, which detects a 2.1-kb transcript. A transcript for the 10-kb
species was detected on the 3 days of gestation critical for development of the
secondary palate (Panel A). Based upon densitometric analysis and normal-
ization to β-actin mRNA levels, there was no significant difference in the level
of expression across this developmental window. In addition, transcripts for
PRDM16/MEL1 could be detected in embryonic heart, liver, brain, and limb
bud tissue, with possible higher expression of the 7-kb transcript in brain tissue
(Panel B). The data presented are representative of three independent
preparations of RNA from each day of gestation.robe (Fig. 4A). A major 10-kb transcript was detected in each
sample, with minor 7 kb and 5 kb transcripts also present with no
apparent differences in levels of expression. The slightly
weaker-intensity band on E14.5 is likely due to loading and/or
membrane transfer differences, since both densitometric analy-
sis and chemiluminescent detection with a CCD camera revealed
no statistically significant differences in the ratios of the
PRDM16/MEL1 transcript to that of β-actin. RNA from tissue
microdissected from E14.5 mouse embryo heart, liver, brain,
and limb bud was also analyzed by Northern blotting with the
PRDM16/MEL1 riboprobe (Fig. 4B). PRDM16/MEL was
expressed in each of these tissues, with signals for all three
splice variants also in evidence.
3.2. Spatial expression of PRDM16/MEL1 mRNA in the
primary and secondary palate
In situ hybridization experiments with a PRDM16/MEL1
antisense riboprobe detected expression in both the primary and
secondary palates (Fig. 5). In addition, PRDM16/MEL1
transcripts were detected in the nasal septum and upper lip.
Interestingly, the expression of PRDM16/MEL1 in the
secondary palate was mainly in the anterior one-half with little
expression detected in the posterior region of the palate. No
signal was observed when a PRDM16/MEL1 sense riboprobe
was used (not shown).
3.3. Effect of PRDM16/MEL1 on TGFβ reporter activation
To determine the role of PRDM16/MEL1 in Smad-dependent
TGFβ signaling, an siRNA-based strategy was used to reduce
the level of PRDM16/MEL1 mRNA in primary cultures of
murine embryonic mesenchyme (MEMM) cells derived from
E13.5 embryonic orofacial tissue. The effect on TGFβ signaling
was then determined in reporter assays with the plasmid, p3TP-
lux, that encodes the plasminogen activator inhibitor promoter
upstream of firefly luciferase. p3TP-lux was co-transfected with
PRDM16/MEL1 siRNAs and the effect on TGFβ-mediated
luciferase synthesis determined (Table 1). Based upon real-time
RT-PCR assays, 100 nM PRDM16/MEL1 siRNA reduced the
Fig. 5. In situ hybridization of embryonic murine orofacial tissue with a
biotinylated PRDM16/MEL1 riboprobe. Whole-mount in situ hybridization of
palate and maxilla of E13.5 murine embryo with PRDM16/MEL1 antisense
riboprobe. Expression of PRDM16/MEL1 mRNA was detected in both the
primary (pp, green arrow) and secondary palates (ps, yellow arrows) in addition
to the nasal septum (ns, yellow arrowhead) and upper lip (ul, green arrowhead).
The anterior one half of the secondary palate stained more intensely than the
posterior one half.
Table 1
Effect of PRDM16/MEL1 knockdown on TGFβ-mediated transcription
Relative luciferase activity
(fold change)
mRNA knockdown
(fold change)
Control siRNA 5.0±0.8 –
PRDM16 siRNA 7.3±1.4 2.2±0.2
Cultured murine embryonic maxillary mesenchymal (MEMM) cells were
transfected with a pool of 4 control or PRDM16/MEL-specific siRNAs, the
TGFβ reporter plasmid, p3TP-lux, and pRL-CMV. Forty-eight hours later, cells
were treated with 2 ng/ml TGFβ for 24 h, after which time cells were lysed and
luciferase activity determined. Data are presented as the mean fold-change of
relative luciferase activity (Firefly luciferase/Renilla luciferase)±standard error
of the mean for three independent experiments, with triplicate samples in each
experiment. There were no statistically significant effects of PRDM16/MEL1
knockdown on Smad-mediated TGFβ signaling (t-test, p=0.238).
818 D.R. Warner et al. / Biochimica et Biophysica Acta 1773 (2007) 814–820level of mRNA an average of 2.2-fold compared to a control
siRNA. The relative luciferase activity following TGFβ stimu-
lation was ∼5-fold for control samples and 7.3-fold for
PRDM16/MEL1 siRNA-transfected MEMM cells. Although
suggestive that PRDM16/MEL1 knockdown increases TGFβ
signaling, the difference was not statistically significant (t-test,
p=0.238). Based upon similarities to both MDS1/Evi1 and
Evi1, both known to affect TGFβ signaling, it is likely that the
weak knockdown of PRDM16/MEL1 by the siRNA was
insufficient to significantly alter TGFβ signaling. Western
blotting with both Smad 2 and anti-phospho-Smad 2 antibodies
of parallel wells did not detect any change in the amount of
phospho-Smad 2 as a result of PRDM16/MEL1 siRNA trans-
fection (not shown).
4. Discussion
The diverse outcomes resulting from activation of the TGFβ
pathway in embryonic tissue is determined by the makeup of
proteins assembled into the transcriptional complex and bound
to target gene promoters. Therefore, to dissect TGFβ signaling
specificity, identification of the individual proteins that are in
these complexes is critical. Many of the cellular processes
involved in orofacial development are under the influence of
TGFβ [2,4,21]. The goal of the current work was to identify
novel Smad binding proteins that confer TGFβ signaling
specificity during orofacial development. The results presented
here demonstrate that PRDM16 (MEL1) is a Smad binding
protein that can bind a number of different Smads, including
TGFβ- and BMP-regulated Smads, in addition to inhibitorySmads. Binding of PRDM16/MEL1 to both regulatory Smads
and to inhibitory Smads would at first appear contradictory.
However, inhibitory Smads are regulated at the level of trans-
cription by TGFβ itself [22]. Therefore, only after prolonged
signaling would Smad 7 levels increase and potentially disrupt
the interaction between PRDM16/MEL1 and regulatory Smads.
PRDM16/MEL1 was first cloned by Mochizuki et al. and
termed MEL1 because of its similarity to MDS1/Evi1 (MDS1/
Evi1-like) which share 56% amino acid identity [23]. Both
proteins have a PR domain, a subclass of the SET domain, so
called for the presence of the regulatory domain present in
PRD1-BF-1 and RIZ1 that may be important in the regulation
of oncogenic potential, particularly in certain types of leukemia
in which PRDM16/MEL1 is aberrantly expressed [24]. The
PRDM gene family contains at least 13 members, each con-
taining a PR domain and a DNA binding domain which is
necessary for direct DNA binding and function [25].
Based upon Northern blotting experiments, several PRDM16/
MEL1 transcripts have been observed [8 kb and 5 kb], leading
to the presumption that alternative splice variants exist [23,26].
Indeed, two major isoforms of PRDM16/MEL1 have been
identified, a 170-kDa, long form (MEL1), and a 150-kDa short
form (MEL1S) that is missing most of the PR domain [27]. As
shown in Fig. 4, several PRDM16/MEL1 transcripts were
expressed in murine embryos, including a major transcript of
10 kb with minor transcripts of 7 kb and 5 kb. Whether these are
the same transcripts as previously observed in human tissue [23]
or whether these represent alternative forms not found in human
tissue is unknown. There appeared to be no temporal regulation
of any of the splice variants. RT-PCR analysis of embryonic
orofacial tissue with oligonucleotide primers targeting the exon
1–2 boundary (the region coding for the PR domain) were
successful in amplifying cDNA from these same samples,
suggesting that the long form is expressed (not shown). These
same primers, and primers spanning the exon 13–14 boundary
were also used to assess the knockdown efficiency of PRDM16/
MEL1 with targeted siRNAs (Table 1).
PRDM16/MEL1 is similar in structure to Evi1 (minus the
PR domain) which has been previously demonstrated to
bind the MH2 domain of Smad 3 through its DNA binding
domain-1 (Zinc finger domain-1) and repress TGFβ signaling
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signaling [29]. Based upon these reports, we predicted that
PRDM16/MEL1 would enhance TGFβ signaling based on its
similarity to MDS1/Evi1. However, siRNA knockdown of
PRDM16/MEL1 led to a small, but statistically insignificant
increase in TGFβ-mediated reporter activity (Table 1). This
indicates the possibility that domains other than the PR domain,
or interaction with additional proteins, such as CtBP in the case
of Evi1 [30] will be important for the signaling outcome from the
interaction between PRDM16/MEL1 and TGFβ Smads. The
weak effect of these siRNAs may be due to the relatively modest
reduction in PRDM16/MEL1 (∼2-fold). Due to technical
limitations, higher concentrations could not be tested, and it is
unclear at this point if greater efficacy of the siRNA approach
would magnify the effect, if any, on TGFß reporter activity. We
are currently investigating in more detail the nature of the impact
of PRDM16/MEL1 on TGFβ signaling, with particular
emphasis on mechanisms of orofacial development. Unlike
Evi1, the interaction between PRDM16/MEL1 and Smads is not
likely through the DNA binding domain-1 since the yeast two-
hybrid clone isolated from the screen was missing this domain,
the PR domain, and the proline-rich region.
Whole-mount in situ hybridizations with a PRDM16/MEL1-
specific riboprobe clearly demonstrate that PRDM16/MEL1 is
expressed in murine embryonic orofacial tissue, but appears to
be restricted to the anterior portion of the secondary palate, along
with strong staining in the primary palate (Fig. 5). Recently,
several studies have focused on the differential expression of
genes along the anterior–posterior axis of the palate and their
role in patterning of the secondary palate [31–33]. Strictly based
upon its location within the developing palate, it is plausible to
propose that PRDM16/MEL1 plays a role in anterior–posterior
patterning of the secondary palate and possibly in differentiation
of the anterior (bony) and posterior (soft) palate. Recently, a
murine mutant generated by whole-animal ENU mutagenesis
with a mutation in the gene for PRDM16/MEL1 [34] presented
with a cleft palate [35]. In addition missense mutations of
PRDM16/MEL1 were found in several cases of non-syndromic
cleft lip/palate [35]. These findings suggest that PRDM16/
MEL1 is critical for palate development.
Few studies have examined the expression pattern of
PRDM16/MEL1 in either adult or embryonic tissue. Recently,
however, Van Campenhout, et al. demonstrated expression of
PRDM16/MEL1 mRNA in migrating hyoid crest cells and
in various stages of Xenopus development, in the otic vesicle,
the developing brain, retinal pigment epithelium of the eye, the
developing heart, and in the developing kidney [36]. Prelimi-
nary analysis of the expression of PRDM16/MEL1 in develop-
ing murine embryos reveals a similar pattern of expression
(Horn, manuscript in preparation).
PRDM16/MEL1 colocalizes with a number of signaling
molecules that have been suggested, or demonstrated to
function in, palatogenesis [e.g. Shox2 [31], Msx1 [33], Osr1,
Osr2, and Pax9 [37]. Of particular note are those involved in the
TGFβ or BMP signaling pathways since both of these utilize
Smads to transduce signals into the nucleus and have the
potential to interact with PRDM16/MEL1. TGFβ3 is expressedin the palate medial edge epithelium and is critical for palatal
fusion [11]. A number of TGFβ and BMP receptors are also
expressed in the palate in patterns that overlap that of PRDM16/
MEL1: Alk-1, Alk-2, Alk-5, and Alk7 [38]. Dudas recently
demonstrated that intact TGFβ signaling in palate epithelium
and mesenchyme is required for palatal shelf fusion [39].
Therefore, PDM16/MEL1 may alter mesenchymal TGFβ
signals in order to enhance the signaling potential of TGFß
and thus alter the gene induction profile necessary for normal
palate fusion. BMP also has important functions in palate
development [40] and the expression of Bmp2 and Bmp4
overlap significantly with that of PRDM16/MEL1. Therefore,
PRDM16/MEL1 may coordinate signaling through two impor-
tant pathways (TGFβ and BMP) necessary for proper palate
development.
Based upon similarities to Evi1, and the observation that
PRDM16/MEL1 is ectopically activated through translocations
in a number of cancer cells, we predict that at least one role for
PRDM16/MEL1 is in the control of the cell cycle progression.
This novel Smad binding protein is expressed in developing
orofacial tissue and modulates TGFβ signaling. The specific
expression pattern within the developing orofacial region, and
in particular the primary and secondary palates, coupled with
preliminary reports of its involvement in human cases of
clefting provide strong evidence that this protein is important
for normal orofacial development. Future studies will focus on
the role of PRDM16/MEL1 in mediating TGFβ dependent
cellular processes such as cell proliferation and extracellular
matrix synthesis, both of which are central to normal orofacial
development.
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